Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | LVGN6051 |
| Trade Name | |
| Synonyms | LVGN-6051|LVGN 6051|Exlinkibart |
| Drug Descriptions |
LVGN6051 is a monoclonal antibody that targets 4-1BB (CD137) and acts as an agonist in the presence of Fc-gammaRIIB, potentially resulting in decreased tumor growth (PMID: 31105267). |
| DrugClasses | TNFRSF9 Antibody 36 |
| CAS Registry Number | 2642171-64-8 |
| NCIT ID | C171541 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Anlotinib + LVGN6051 | Anlotinib LVGN6051 | 0 | 0 |
| Bevacizumab + Cyclophosphamide + LVGN3616 + LVGN6051 | Bevacizumab Cyclophosphamide LVGN3616 LVGN6051 | 0 | 1 |
| Bevacizumab + Cyclophosphamide + LVGN3616 + LVGN6051 + LVGN7409 | Bevacizumab Cyclophosphamide LVGN3616 LVGN6051 LVGN7409 | 0 | 1 |
| LVGN3616 + LVGN6051 + LVGN7409 + Nab-paclitaxel | LVGN3616 LVGN6051 LVGN7409 Nab-paclitaxel | 0 | 1 |
| LVGN6051 | LVGN6051 | 0 | 1 |
| LVGN6051 + Pembrolizumab | LVGN6051 Pembrolizumab | 0 | 0 |